Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines

Cellular Oncology

Volumn 36, Issue 5, 2013, Pages 351-362

  Duijkers, Floor A M ^a   De Menezes, Renee X ^a,b   Goossens Beumer, Inès J ^a   Stumpel, Dominique J P M ^a   Admiraal, Pieter ^a   Pieters, Rob ^a   Meijerink, Jules P P ^a   Van Noesel, Max M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Demethylating agent; Epigenetics; Ewing sarcoma; HDAC inhibitor; Methylation; Neuroblastoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN P53; TRICHOSTATIN A;

ANIMAL CELL; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROECTODERMAL TUMORS; POLYMERASE CHAIN REACTION;

EID: 84890244393     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0140-x     Document Type: Article

References (63)

1. S.B. Baylin, P.A. Jones, A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11(10), 726-734 (2011)
2. A.P. Feinberg, B. Tycko, The history of cancer epigenetics. Nat Rev Cancer 4(2), 143-153 (2004)
3. J.P. Issa, H.M. Kantarjian, Targeting DNA methylation. Clin Cancer Res 15(12), 3938-3946 (2009)
4. R.L. Piekarz, S.E. Bates, Epigenetic modifiers: Basic understanding and clinical development. Clin Cancer Res 15(12), 3918-3926 (2009)
5. H.M. Prince, M.J. Bishton, S.J. Harrison, Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15(12), 3958-3969 (2009)
6. G. Chai, L. Li,W. Zhou, L.Wu, Y. Zhao, D.Wang, S. Lu, Y. Yu, H. Wang, M.A. McNutt, Y.G. Hu, Y. Chen, Y. Yang, X. Wu, G.A. Otterson, W.G. Zhu, HDAC inhibitors act with 5-aza-2'- deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 3(6), e2445 (2008)
7. M. Dickinson, R.W. Johnstone, H.M. Prince, Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect. Invest New Drugs 28(Suppl 1), S3-20 (2010)
8. N. Steele, P. Finn, R. Brown, J.A. Plumb, Combined inhibition of DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity in vivo. Br J Cancer 5, 758- 763 (2009)
9. M. Bishton, M. Kenealy, R. Johnstone, W. Rasheed, H.M. Prince, Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents. Expert Rev Anticancer Ther 7(10), 1439-1449 (2007)
10. W. Blum, R.B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, C. Plass, S.M. Devine, N.A. Heerema, A. Murgo, K.K. Chan, M.R. Grever, J.C. Byrd, G. Marcucci, Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25(25), 3884-3891 (2007)
11. M. Bots, R.W. Johnstone, Rational combinations using HDAC inhibitors. Clin Cancer Res 15(12), 3970-3977 (2009)
12. G. Garcia-Manero, H.M. Kantarjian, B. Sanchez-Gonzalez, H. Yang, G. Rosner, S. Verstovsek, M. Rytting, W.G. Wierda, F. Ravandi, C. Koller, L. Xiao, S. Faderl, Z. Estrov, J. Cortes, S. O'Brien, E. Estey, C. Bueso-Ramos, J. Fiorentino, E. Jabbou, J.P. Issa, Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271- 3279 (2006)
13. R.W. Johnstone, Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1(4), 287-299 (2002)
14. A. Insinga, S. Minucci, P.G. Pelicci, Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 4(6), 741-743 (2005)
15. A. Insinga, S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci, P.G. Pelicci, Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11(1), 71-76 (2005)
16. P. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, W.K. Kelly, Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1(3), 194-202 (2001)
17. J. E. Fraczek, M. Vinken, D. Tourwe, T. Vanhaecke,V. Rogiers, Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes. Invest New Drugs (2011)
18. F. Lyko, R. Brown, DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97(20), 1498-1506 (2005)
19. H.C. Tsai, H. Li, L. Van Neste, Y. Cai, C. Robert, F.V. Rassool, J.J. Shin, K.M. Harbom, R. Beaty, E. Pappou, J. Harris, R.W. Yen, N. Ahuja, M.V. Brock, V. Stearns, D. Feller-Kopman, L.B. Yarmus, D. Feller-Kopman, L.B. Yarmus, Y.C. Lin, A.L. Welm, J.P. Issa, I. Minn, W. Matsui, Y.Y. Jang, S.J. Sharkis, S.B. Baylin, C.A. Zahnow, Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3), 430-446 (2012)
20. J. Lopez, M. Percharde, H.M. Coley, A. Webb, T. Crook, The context and potential of epigenetics in oncology. Br J Cancer 4, 571-577 (2009)
21. T. Qin, J. Jelinek, J. Si, J. Shu, J.P. Issa, Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009)
22. T. Qin, E.M. Youssef, J. Jelinek, R. Chen, A.S. Yang, G. Garcia- Manero, J.P. Issa, Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13(14), 4225- 4232 (2007)
23. E.E. Cameron, K.E. Bachman, S. Myohanen, J.G. Herman, S.B. Baylin, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21(1), 103-107 (1999)
24. O. Galm, J.G. Herman, S.B. Baylin, The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 20(1), 1- 13 (2006)
25. T.J.Walton, G. Li, R. Seth, S.E. McArdle, M.C. Bishop, R.C. Rees, DNA demethylation and histone deacetylation inhibition cooperate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68(2), 210-222 (2008)
26. H.C. Tsai, S.B. Baylin, Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21(3), 502-517 (2011)
27. C.D. Margetts, M. Morris, D. Astuti, D.C. Gentle, A. Cascon, F.E. McRonald, D. Catchpoole, M. Robledo, H.P. Neumann, F. Latif, E.R. Maher, Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocr Relat Cancer 15(3), 777-786 (2008)
28. B. Banelli, I. Gelvi, A. Di Vinci, P. Scaruffi, I. Casciano, G. Allemanni, S. Bonassi, G.P. Tonini, M. Romani, Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 24(36), 5619-5628 (2005)
29. J. Hoebeeck, E. Michels, F. Pattyn, V. Combaret, J. Vermeulen, N. Yigit, C. Hoyoux, G. Laureys, A. De Paepe, F. Speleman, J. Vandesompele, Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 273(2), 336-346 (2009)
30. K. Harada, S. Toyooka, A. Maitra, R. Maruyama, K.O. Toyooka, C.F. Timmons, G.E. Tomlinson, D. Mastrangelo, R.J. Hay, J.D. Minna, A.F. Gazdar, Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 21(27), 4345-4349 (2002)
31. M. Abe, M. Ohira, A. Kaneda, Y. Yagi, S. Yamamoto, Y. Kitano, T. Takato, A. Nakagawara, T. Ushijima, CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65(3), 828-834 (2005)
32. T. Teitz, T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet,V.A.Valentine, F.G. Behm, A.T. Look, J.M. Lahti, V.J. Kidd, Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6(5), 529-535 (2000)
33. P. Gonzalez-Gomez, M.J. Bello, J. Lomas, D. Arjona, M.E. Alonso, C. Aminoso, I. Lopez-Marin, N.P. Anselmo, J.L. Sarasa,M. Gutierrez, C. Casartelli, J.A. Rey, Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39(10), 1478-1485 (2003)
34. A. Decock, M. Ongenaert, J. Vandesompele, F. Speleman, Neuroblastoma epigenetics: From candidate gene approaches to genomewide screenings. Epigenetics 6(8), 962-970 (2011)
35. M.M. van Noesel, S. van Bezouw, G.S. Salomons, P.A. Voute, R. Pieters, S.B. Baylin, J.G. Herman, R. Versteeg, Tumor-specific downregulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62(7), 2157-2161 (2002)
36. M.M. van Noesel, S. van Bezouw, P.A. Voute, J.G. Herman, R. Pieters, R. Versteeg, Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 38(3), 226-233 (2003)
37. H. Caren, A. Djos, M. Nethander, R. M. Sjoberg, P. Kogner, C. Enstrom, S. Nilsson,T. Martinsson, Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 11:(1): P. 66 (
38. P. G. Buckley, S. Das, K. Bryan, K. M. Watters, L. Alcock, J. Koster, R. Versteeg,R. L. Stallings, Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer
39. D.M. Murphy, P.G. Buckley, K. Bryan, S. Das, L. Alcock, N.H. Foley, S. Prenter, I. Bray, K.M.Watters, D. Higgins, R.L. Stallings, Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4(12), e8154 (2009)
40. M. Berdasco, S. Ropero, F. Setien, M.F. Fraga, P. Lapunzina, R. Losson, M. Alaminos, N.K. Cheung, N. Rahman, M. Esteller, Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 106(51), 21830-21835 (2009)
41. Y. Sugino, A. Misawa, J. Inoue, M. Kitagawa, H. Hosoi, T. Sugimoto, I. Imoto, J. Inazawa, Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 26(53), 7401-7413 (2007)
42. R.E. George, J.M. Lahti, P.C. Adamson, K. Zhu, D. Finkelstein, A.M. Ingle, J.M. Reid, M. Krailo, D. Neuberg, S.M. Blaney, L. Diller, Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 55(4), 629-638 (2010)
43. A. Aparicio, C.A. Eads, L.A. Leong, P.W. Laird, E.M. Newman, T.W. Synold, S.D. Baker, M. Zhao, J.S. Weber, Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol 51(3), 231-239 (2003)
44. H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, A. Ferrajoli,W.Wierda, J. Shan, J. Davis, F. Giles, H.I. Saba, J.P. Issa, Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52-57 (2007)
45. A. Thibault, W.D. Figg, R.C. Bergan, R.M. Lush, C.E. Myers, A. Tompkins, E. Reed, D. Samid, A phase II study of 5-aza- 2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84(1), 87-89 (1998)
46. W. D. Johnson, A pharmacokinetic/pharmacodynamic approach to evaluating the safety of zebularine in non-human primates Proc Amer Assoc Cancer Res. 47: (2006)
47. J.L. Holleran, R.A. Parise, E. Joseph, J.L. Eiseman, J.M. Covey, E.R. Glaze, A.V. Lyubimov, Y.F. Chen, D.Z. D'Argenio, M.J. Egorin, Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11(10), 3862-3868 (2005)
48. S. Shichijo, A. Yamada, K. Sagawa, O. Iwamoto, M. Sakata, K. Nagai, K. Itoh, Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine. Jpn J Cancer Res 87(7), 751-756 (1996)
49. F. Condorelli, I. Gnemmi, A. Vallario, A.A. Genazzani, P.L. Canonico, Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153(4), 657-668 (2008)
50. C. De Smet, C. Lurquin, B. Lethe, V. Martelange, T. Boon, DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19(11), 7327-7335 (1999)
51. P.G. Buckley, S. Das, K. Bryan, K.M.Watters, L. Alcock, J. Koster, R. Versteeg, R.L. Stallings, Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 128(10), 2296-2305 (2011)
52. V. M. Komashko,P. J. Farnham, 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics. 5:(3): (2010)
53. Y. Gomyo, J. Sasaki, C. Branch, J.A. Roth, T. Mukhopadhyay, 5- aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23(40), 6779-6787 (2004)
54. M.S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J.G. Herman, W.L. Gerald, Y.A. Lazebnik, C. Cordon-Cardo, S.W. Lowe, Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817), 207-211 (2001)
55. W.G. Zhu, Z. Dai, H. Ding, K. Srinivasan, J. Hall, W. Duan, M.A. Villalona-Calero, C. Plass, G.A. Otterson, Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene 20(53), 7787-7796 (2001)
56. A. Doi, I.H. Park, B.Wen, P. Murakami, M.J. Aryee, R. Irizarry, B. Herb, C. Ladd-Acosta, J. Rho, S. Loewer, J. Miller, T. Schlaeger, G.Q. Daley, A.P. Feinberg, Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41(12), 1350-1353 (2009)
57. A. Meissner, T.S. Mikkelsen, H. Gu, M. Wernig, J. Hanna, A. Sivachenko, X. Zhang, B.E. Bernstein, C. Nusbaum, D.B. Jaffe, A. Gnirke, R. Jaenisch, E.S. Lander, Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205), 766-770 (2008)
58. R. Lister, M. Pelizzola, R.H. Dowen, R.D. Hawkins, G. Hon, J. Tonti-Filippini, J.R. Nery, L. Lee, Z. Ye, Q.M. Ngo, L. Edsall, J. Antosiewicz-Bourget, R. Stewart, V. Ruotti, A.H. Millar, J.A. Thomson, B. Ren, J.R. Ecker, Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009)
59. E.M. Klenova, H.C. Morse 3rd, R. Ohlsson, V.V. Lobanenkov, The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12(5), 399-414 (2002)
60. S. Vatolin, Z. Abdullaev, S.D. Pack, P.T. Flanagan, M. Custer, D.I. Loukinov, E. Pugacheva, J.A. Hong, H. Morse 3rd, D.S. Schrump, J.I. Risinger, J.C. Barrett, V.V. Lobanenkov, Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65(17), 7751- 7762 (2005)
61. R. Ohlsson, R. Renkawitz, V. Lobanenkov, CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17(9), 520-527 (2001)
62. A. Woloszynska-Read, S.R. James, C. Song, B. Jin, K. Odunsi, A.R. Karpf, BORIS/CTCFL expression is insufficient for cancergermline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 10(6) (2010)
63. J.P. Issa, G. Garcia-Manero, F.J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C.S. Rosenfeld, J. Cortes, H.M. Kantarjian, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5), 1635- 1640 (2004)